{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-003043","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.150427+00:00","generated_at":"2026-05-27T22:38:26.438693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanara MedTech reports Q4 prelim net revenue up 45-48% YoY; FY up 32-33%","bullets":["Q4 2024 net revenue expected $25.7M-$26.2M, a 45-48% increase YoY.","Full year 2024 net revenue expected $86.0M-$86.5M, up 32-33% YoY.","BIASURGE sales benefited from ~$1.8M in temporary demand due to hurricane-related IV fluid shortages; expects normalization in Q1 2025.","Cash at Dec 31, 2024: $15.9M; debt $30.5M; $24.5M available borrowing capacity.","Appointed Keith Myers (former LHC Group CEO) to Board on Oct 4, 2024; filed 11 provisional patent applications in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-003043","json":"https://secwatch.observer/filing/0001493152-25-003043.json","markdown":"https://secwatch.observer/filing/0001493152-25-003043.md","text":"https://secwatch.observer/filing/0001493152-25-003043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315225003043/0001493152-25-003043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315225003043/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:38:26.438693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}